Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy

Similar documents
Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System

STARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant

Opadry Enteric. Application Data. Drug Release from Acrylic-Based Opadry Enteric (94 Series) Coated Tablets INTRODUCTION MATERIALS AND METHODS

Designed and manufactured specifically for pharmaceutical capsule filling

Table 1. Coating Parameters

Comparative Evaluation of Enteric Film Coatings Applied in Organic Solvents

Protection and Processing of a Highly Hygroscopic Herbal Extract by Drug Layering and Film Coating

STARCH Application Data

The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation

In-Vitro Bioequivalence Studies for Oral Solid Dose products using the Morphologi G3-ID

Content Uniformity of Direct Compression tablets

The Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose Matrices

Lactose Free, Direct Compression Formulation Used to Produce Loratadine (10 mg) Tablets

Direct Compression Formulation Using Starch 1500 with Ranitidine HCl (150 mg) Tablets, Film Coated with Opadry II (85F Series)

Figure 1: SEM Mannogem EZ (1000x)

Excipient Considerations for Continuous Manufacturing Implementation

Technical brochure StarLac

SENTRY TM POLYOX Water Soluble Resins

Direct Compression. With the right ingredients it s a simple, cost-effective manufacturing process

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

FT-Raman Surface Mapping of Remineralized Artificial Dental Caries

TECHNICAL INFORMATION RxCIPIENTS FM A versatile excipient for orally disintegrating tablet (ODT) formulations

OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE. Technical brochure MicroceLac 100

Narrowing the gap between clinical capsule formulations and commercial film-coated tablets

Technical brochure CombiLac

TEPZZ _7584 A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/00 ( ) A61K 31/439 (2006.

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON LAMIVUDINE TABLETS

Ingredients adapted to a fit for use model. APIs allowed the fit for use strategy to work. There has been a shift to designed for purpose

Everything for Inhalation

Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Co-Processed Excipients: Regulatory Challenges. Carl Mroz Colorcon Limited June 2009

EMTRICITABINE AND TENOFOVIR TABLETS

DRAFT MONOGRAPH FOR THE INTERNATIONAL PHARMACOPOEIA EFAVIRENZ, EMTRICITABINE AND TENOFOVIR TABLETS

Analysis and stability of polymorphs in tablets: The case of Risperidone

Effect of Compaction Forces on Powder Bed Permeability of Magnesium Silicate "Common Excipient Mixture"

EP B1 (19) (11) EP B1 (12) EUROPEAN PATENT SPECIFICATION

The influence of lactose particle size on dry powder inhalation performance

Pharma & Food Solutions. POLYOX TM Water Soluble Resins Combining Flexibility with Consistency

RP-HPLC Method Development and Validation of Abacavir Sulphate in Bulk and Tablet Dosage Form

Ingredient Listing Qty. Unit NDC # Supplier

Hydrocortisone 2%, Hydroquinone 6%, Kojic Acid 4%, Salicylic Acid 4%, Tretinoin 0.01% Topical Gel (Suspension, 20 g)

CYCLOSERINI CAPSULAE - CYCLOSERINE CAPSULES (AUGUST 2015)

TENOFOVIR TABLETS: Final text for addition to The International Pharmacopoeia (June 2010)

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR ESTIMATION OF LACOSAMIDE IN BULK AND ITS PHARMACEUTICAL FORMULATION

SUGGESTED FORMULATION. Lot Number. Expiry Date. Ingredient Listing Qty. Unit NDC # Supplier

LEVONORGESTREL AND ETHINYLESTRADIOL TABLETS. (January 2012) DRAFT FOR COMMENT

Ingredient Listing Qty. Unit NDC # Supplier g. Sterile Preparation

ISSN: ; CODEN ECJHAO E-Journal of Chemistry 2011, 8(3),

ACQUITY UPLC WITH PDA DETECTION: DETERMINING THE SENSITIVITY LIMITS OF OXYBUTYNIN AND RELATED COMPOUNDS

CONTENTS PAGE. Please note: Preface Matrix system Selection of METOLOSE grades Specifications

NEAR INFRARED TRANSMISSION SPECTROSCOPY AS APPLIED TO FATS AND OIL

Ingredient Listing Qty. Unit NDC # Supplier TBD. Sterile Preparation

Fluoxetine Hydrochloride 5.6 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Chewable Treats)

DRAFT PROPOSAL FOR THE INTERNATIONAL PHARMACOPOEIA: CARBAMAZEPINI COMPRESSI - CARBAMAZEPINE TABLETS

STUDY OF THE DETERIORATION OF ASPIRIN IN THE PRESENCE OF VARIOUS EXCIPIENTS

Novel Application of an Old Excipient L-Leucine- Improving Physical and. Aerosolization Stability of Spray Dried Amorphous DPI Formulations.

Methimazole 5 mg Oral Chewable Treats (Solid Suspension, 60 x 1 ml Treats) FIN F v2. Ingredient Listing Qty. Unit NDC # Supplier

Validation of Changes to the USP Assay Method for Ibuprofen Tablets

EUDRAGIT E 100, EUDRAGIT E PO and

Draft monograph for inclusion in. The International Pharmacopoeia. Dextromethorphani solutionum peroralum - Dextromethorphan oral solution

Ingredient Listing Qty. Unit NDC # Supplier ml

FLORITER. New Technology for Innovative Formulation Design.

SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS Draft proposal for The International Pharmacopoeia (September 2010)

Material Safety Data Sheet

J Pharm Sci Bioscientific Res (4): ISSN NO

Wettable Magnesium Stearate. What Are Customers Looking for in Selecting Pharmaceutical Lubricants?

CLINDAMYCIN PALMITATE

J.Ayyappan et al, /J. Pharm. Sci. & Res. Vol.2 (7), 2010,

CHAPTER 5 CHARACTERIZATION OF ZINC OXIDE NANO- PARTICLES

Probing for Packaging Migrants in a Pharmaceutical Impurities Assay Using UHPLC with UV and Mass Detection INTRODUCTION

The unlocked synergy of DFE Pharma MCC

RITONAVIRI COMPRESSI RITONAVIR TABLETS. Final text for addition to The International Pharmacopoeia (July 2012)

DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD ESTIMATION OF TOLVAPTAN IN BULK PHARMACEUTICAL FORMULATION

CHAPTER INTRODUCTION OF DOSAGE FORM AND LITERATURE REVIEW

Determination of Tetracyclines in Chicken by Solid-Phase Extraction and High-Performance Liquid Chromatography

Influence of blender type on the performance of ternary dry powder inhaler formulations

The binding performance of DFE Pharma Starch

USP Method Transfer of Ziprasidone HCl from HPLC to UPLC

Asian Journal of Pharmaceutical Analysis and Medicinal Chemistry Journal home page:

nitrogen Advanced technology management TECHNOLOGY PAST THE POINT OF NUTRITION to increase N efficiencies through improved agronomics & handling

Using laser diffraction to characterize casein micelles and fat globules in milk

VIVAPHARM PVP/VA. Copovidone, Ph.Eur. USP/NF, JPE, E. The Ultimate Tablet Binder for All Processing Technologies

FlexaTrac -NTA C H E L A T I N G A G E N T

ORAL DOSAGE OVERVIEW

Bioavailability enhancement of poorly soluble APIs. Enhanced solubilization out of solid glassy solutions prepared by Hot-Melt Extrusion

Huber Free-Flow Additives

Measuring Exosome Stability with Nanoparticle Tracking Analysis

Ingredient Listing Qty. Unit NDC # Supplier. q.s. to ml

LAB.2. Tablet Production Methods

Technical brochure InhaLac

Improving performance of high fat containing and soft powders with AEROSIL and SIPERNAT products. Technical Information TI 1405

ZIDOVUDINE, LAMIVUDINE AND ABACAVIR TABLETS Draft proposal for The International Pharmacopoeia (September 2006)

ACUMER 4300 Polymer. Scale Inhibitor and Dispersant for Calcium Carbonate and Calcium Sulfate Control

DISSOLUTION TESTING - Exploring the Link Between Particle Size & Dissolution Behavior for OINDPs

Ingredient Listing Qty. Unit NDC # Supplier. Sterile Preparation

Food protein powders classification and discrimination by FTIR spectroscopy and principal component analysis

Development, Estimation and Validation of Lisinopril in Bulk and its Pharmaceutical Formulation by HPLC Method

ACUMER 4161 Phosphinopolycarboxylic Acid Scale Inhibitor and Dispersant

Transcription:

Starch 1500 Application Data Partially Pregelatinized Maize Starch Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy OBJECTIVE To characterize the physical uniformity and chemical content uniformity of a very low dose of indomethacin (0.5%) within Starch 1500, partially pregelatinized maize starch, in comparison with spray dried lactose (FastFlo) and dibasic calcium phosphate, dihydrate (Emcompress) using a novel Raman spectroscopy mapping technique. To identify key excipient properties that promotes blend uniformity and explains why Starch 1500 improves content uniformity of low dose drugs. BACKGROUND Starch 1500 is a multifunctional excipient with bulking, binding and disintegrating capability. It has been previously shown that Starch 1500, when pre-mixed with an active pharmaceutical ingredient (API), yielded excellent content uniformity on a production scale of 4 million tablets. The average assay of the tablets was 99% of label claim with a variation of 2% RSD, even though the API dose was only 0.07% (w/w) of the formulation 1. The work presented here confirms the ability of Starch 1500 to promote content uniformity and provides insights into the reasons for this performance. Using a mapping technique in conjunction with chemical assay enabled the visualization of the physical/spatial and actual distribution of the API in the blend sample. METHODOLOGY Blending: Blends of indomethacin [m.w. 357.79, calculated log P 4.18, D (v, 4,3) 0.749 μm)] and pregelatinized starch (Starch 1500, Colorcon) spray dried lactose (FastFlo, Foremost) or dibasic calcium phosphate, dihydrate (Emcompress, JRS Pharma) were dry blended in an Apex double cone blender for 10 minutes. Samples (200 mg) were removed in triplicate from different locations of the powder bed in the blender using a stratified sampling technique. Starch 1500-1 -

Scanning Electron Microscopy (SEM): SEM micrographs were obtained for indomethacin, Starch 1500, FastFlo and Emcompress, and the blends thereof with a Cambridge Instruments Stereoscan S-360 Scanning electron microscope (Cambridge Instruments, Cambridge, UK). Samples were gold coated using an Edwards S150 b sputter coater. The images were used to approximate particle size and investigate the nature of the interaction between the excipients and the API. Laser Diffraction: The particle size distributions of the excipients and the API were determined in a dry state by laser diffraction, using a Malvern Mastersizer 2000 fitted with a Sirrocco dry powder flow accessory (Malvern Instruments, Worcs, UK). The results were compared to those obtained by SEM to confirm particle size. FT-Raman Spectroscopy mapping: FT-Raman spectra of indomethacin in the excipient blends were obtained between 0 and 4000 cm-1 using a Thermo-Nicolet NXR FT-Raman Spectrometer, equipped with an NXR Genie detector (liquid nitrogen cooled) and a computer controlled mapping stage. Vibrational bands at 1698 cm-1 (indomethacin), 363 cm-1 (FastFlo), 478 cm-1 (Starch 1500) and 988 cm-1 (Emcompress) were used for analyses. Initial data acquisition was by Smart ARK and OMNIC software. The data were subsequently analyzed using the InSight chemometrics software package. A standard configuration was used to obtain a Raman spectrum from different small areas of the active blend from which FT-Raman spectroscopic spatial maps were obtained. Chemical Assay: The chemical content of indomethacin in the sampled blends was analyzed with the aid of a Waters Acquity UPLC System (Waters Corporation, MA, USA) at 254 nm using a 0.1 M phosphate buffer in acetonitrile/ water mobile phase. The % RSD for replicate standard injections were not more than 2.0 %, and the USP plate count was not less than 1488. RESULTS & DISCUSSION Particle Characteristics by Laser Sizing and SEM The particle sizes (in microns) of the materials obtained by laser sizing are given in the table below. The particle characteristics of the materials as obtained by SEM are given in the table below. Some of the surface features, which are expected to affect the interaction between the active and the excipient, are also presented. Starch 1500-2 -

The particle sizes obtained from both techniques are in very good agreement. There are some larger particles of indomethacin than were observed by SEM. However, with the analysis of a larger sample size, the particle size range determined by laser diffraction is more representative than the size range by SEM. Starch 1500-3 -

The micrographs below show what is believed to be the interaction between indomethacin and the different excipients: It can be seen that the indomethacin particles are attached to the surface and nestling in the crevices of Starch 1500 particles. There are more discrete fine particles of indomethacin observed in the case of Starch 1500 as compared to agglomerates of indomethacin in the FastFlo and Emcompress samples. Chemical Assay of Indomethacin: Data for the blend uniformity assay (n=6 positions within the blender) of indomethacin in Starch 1500, FastFlo and Emcompress are summarized in the table below: The blend with Starch 1500 had the highest uniformity of indomethacin distribution followed by FastFlo and Emcompress. The high average assay and low %RSD for the blend containing Starch 1500, at a very short mixing time (10 min.), have confirmed the postulations above. Spatial Distribution of Indomethacin by Raman Mapping: The physical distribution of indomethacin in the blend is shown in typical Raman maps below. Starch 1500-4 -

In each of the Raman maps, the marker chosen was indomethacin. The red and yellow regions indicate the presence of indomethacin, while green and blue indicate the lack of indomethacin. It is postulated that the yellow is indicative of indomethacin further from the surface. Nine Raman maps were plotted for each of the three excipient-indomethacin blends. These maps showed the following trends: indomethacin was most uniformly dispersed in the Starch 1500 blends lactose blends exhibited good uniformity; however, the level of agglomeration was much higher calcium phosphate blends had the poorest uniformity and the highest level of agglomeration Starch 1500-5 -

Powered by TCPDF (www.tcpdf.org) CONCLUSIONS The content uniformity of very low doses of indomethacin in three excipient blends can be characterized by FT-Raman mapping, SEM and chemical assay. It was demonstrated via all three methods that Starch 1500 consistently yielded blends with significantly better homogeneity and minimal API agglomeration compared with lactose (FastFlo) and dibasic calcium phosphate dihydrate (Emcompress). The ability for Starch 1500 to achieve good homogeneity of the API was ascribed to a uniform distribution of fine particles of API nestling into crevices of Starch 1500 substrate. The moisture contained within Starch 1500 may mediate strong adsorption of active within the crevices via a hydrogen bonding mechanism. ACKNOWLEDGEMENT The authors wish to thank Jennifer Payne and David Ferrizzi of Colorcon for the chemical assay work. REFERENCES 1. Ahmed H, Shah N 2000. Amer. Pharm. Rev. 3(3):1-5. The information contained herein, to the best of Colorcon, Inc. s knowledge is true and accurate. Any recommendations or suggestions of Colorcon, Inc. with regard to the products provided by Colorcon, Inc. are made without warranty, either implied or expressed, because of the variations in methods, conditions and equipment which may be used in commercially processing the products, and no such warranties are made for the suitability of the products for any applications that you may have disclosed. Colorcon, Inc. shall not be liable for loss of profit or for incidental, special or consequential loss or damages. Colorcon, Inc. makes no warranty, either expressed or implied, that the use of the products provided by Colorcon, Inc., will not infringe any trademark, trade name, copyright, patent or other rights held by any third person or entity when used in the customer s application. For more information, contact your Colorcon representative or call: North America Europe/Middle East/Africa Asia Pacific Latin America +1-215-699-7733 +44-(0)-1322-293000 +65-6438-0318 +54-11-4552-1565 BPSI Holdings LLC, 2009. The information contained in this document is proprietary to Colorcon, Inc. and may not be used or disseminated inappropriately. All trademarks, except where noted, are property of BPSI Holdings LLC. ads_starch1500_indometh_v1_02.2010 You can also visit our website at www.colorcon.com Starch 1500-6 -